Capmatinib has 7 known drug interactions based on U.S. FDA drug labeling data. 3 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Cyp3a Inducers, Rosuvastatin, Rosuvastatin Calcium. Patients taking Capmatinib should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 7
- Major
- 3
- Moderate
- 4
Major (3)
- Capmatinib + Cyp3a Inducers— Coadministration with strong CYP3A inducers decreased capmatinib exposure, which may decrease TABRECTA anti-tumor activi…
- Capmatinib + Rosuvastatin— Capmatinib increased rosuvastatin exposure more than 2.1-fold, increasing the risk of myopathy and rhabdomyolysis. Do no…
- Capmatinib + Rosuvastatin Calcium— Capmatinib increases rosuvastatin exposure more than 2.1-fold, increasing risk of myopathy and rhabdomyolysis. Do not ex…
Moderate (4)
- Capmatinib + Breast Cancer Resistance Protein (Bcrp) Substrates— Coadministration increased BCRP substrate exposure, which may increase adverse reactions. Decrease substrate dosage if c…
- Capmatinib + Mao Inhibitors— Coadministration with strong CYP3A inhibitors increased capmatinib exposure, which may increase the incidence and severi…
- Capmatinib + Mate1 Substrates— Coadministration may increase MATE1 substrate exposure, which may increase adverse reactions. Decrease substrate dosage …
- Capmatinib + P-Gp Or Bcrp Substrates— Coadministration increased P-gp substrate exposure, which may increase adverse reactions. Decrease substrate dosage if c…